Text size :

Drugs: Prix Galien Italy to Italfarmaco for therapy in rare disease (2)

ADNKRONOS

November 4, 2026

(Adnkronos Health) – “The fruit of Italian research, givinostat – reads the award’s motivation – represents a therapeutic innovation in Duchenne muscular dystrophy because it introduces a different mechanism of action, independent of the specific genetic mutation, with potential applicability to a broad population of eligible patients according to authorized indications. In association with corticosteroids, it has been shown to slow the progression of the disease and contribute to the more prolonged maintenance of motor function and autonomy, addressing a significant therapeutic need in the field of rare diseases, with a significant impact on the quality of life of patients and their families.”

Duchenne muscular dystrophy is a rare genetic neuromuscular disease that affects almost exclusively male children and is caused by the absence or severe deficiency of dystrophin. When this protein is absent or does not function correctly, muscle fibers become more fragile and, over time, an inflammatory process is activated with the replacement of muscle tissue with fibrous tissue.

“The progression of the disease leads over time to a significant loss of muscle strength, movement capacity, and autonomy – emphasizes Eugenio Maria Mercuri, full professor at the Catholic University of the Sacred Heart –. Patients also face serious complications such as cardiomyopathies, respiratory and neurological problems, with a significant impact on cognitive function. Givinostat, which acts on the cellular mechanisms that contribute to muscle damage, is an important step forward in treatment because it significantly slows down the progression of the disease. The drug belongs to the class of histone deacetylase inhibitors, proteins that regulate the activity of numerous genes. One of the aspects that characterize the molecule is the possibility of offering a therapeutic opportunity regardless of the specific genetic mutation, thus expanding the number of patients who can benefit from the treatment and contributing to preserving patients’ motor function and autonomy over time.”

Jiji Press

Related

Page TOP